November 14, 2025 7:55am

Based on the market and sector sell-offs, government shutdown, fear, investors' risk tolerance, uncertainties about the state of the economy, LPS (loss-per-share) earnings, obscured risks, breath and confidence confusion, debt financing pressures, political i.e., tariff legal uncertainties, potential Fed rate cut pass, index depreciation, valuation declines, etc., with no need for further etc. …

Don’t let those doors’ knobs hit you where the dog has already bit you!

Earnings: Precigen (PGEN) reported

Pre-open Signals: 2 Positive and 7 Negative Indications and a lot of drops

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

“I hate to be considered negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but, I am mostly EARLY!”

Thursday’s RMi Closing Bell: Selling Pressure … https://www.regmedinvestors.com/articles/14195

RMi Research Note: Harvard Apparatus GT (OTCQB): Broke … https://www.regmedinvestors.com/articles/13812

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Friday: The pre-open Dow futures are DOWN -0.57% or (-269 points), the S&P futures are DOWN -0.97% or (-65 points) and the Nasdaq futures are DOWN -1.46% or (-367 points)

  • Stock futures were falling, Friday 11/14
  • European markets fell,
  • Asia Pacific markets opened lower and continued to decline

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -797.60 points or -1.65%, the S&P closed DOWN -113.43 points or -1.66% while the Nasdaq closed DOWN -536.102 points or -2.29%
  • Wednesday: The Dow closed UP +326.86 points or +0.68%, the S&P closed UP +4.31 points or +0.06% while the Nasdaq closed DOWN -61.844 points or -0.26%
  • Tuesday: The Dow closed UP +559.33 points or +1.18%, the S&P closed UP +14.18 points or +0.21% while the Nasdaq closed DOWN -58.874 points or -0.25%
  • Monday: The Dow closed UP +381.53 points or +0.81%, the S&P closed UP +103.63 points or +1.54% while the Nasdaq closed UP +522.637 points or +2.27%
  • Last week: The S&P 500 was down -1.7%, the Dow -1.3% and the Nasdaq -3%
  • The previous week: The S&P 500 was up 1.5%, the Dow +0.9% and the Nasdaq is up +3.2%
  • Last month: the S&P 500 was up +2.3%, the Nasdaq’s +4.7% and the Dow’s is up +2.5%.

 

Q4 – November, 3 positive and 6 negative sessions

  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Alnylam Pharmaceuticals (ALNY +$1.23 after Wednesday’s +$0.79, Tuesday’s +$10.25 and Monday’s -$1.00 with a negative -$3.97 or -0.87% pre-open

Lenz Therapeutics (LENZ +$0.99 after Wednesday’s -$0.95 any Tuesday’s +$3.26 with a positive +$0.51 or +1.93% pre-open

Vertex (VRTX) closed up +$0.33 after Wednesday’s+$4.97, Tuesday’s +$4.86 and Monday’s +$11.73 with a positive +$5.46 or +1.25% pre-open

uniQure NV (QURE) closed up +$0.22 after Wednesday’s -$0.72 and Tuesday’s +$4.57 with a negative -$1.34 or -4.42% pre-open

BioNTech (BNTX) closed down -$7.82 after Wednesday’s+$3.05, Tuesday’s +$3.58 and Monday’s +$1.93 with a negative -$0.38 or -0.37% pre-open

Moderna (MRNA) closed down -$1.75 after Wednesday’s+$0.30 and Tuesday’s +$1.17 with a negative -$0.39 or +0.40% pre-open

CRISPR Therapeutics (CRSP) closed down -$1.08 after Wednesday’s-$3.02 with a negative -$1.96 or -3.83% pre-open

Mesoblast (MESO) closed down -$0.78 with a negative -$0.28 or -1.88% pre-open

Ultragenyx Pharmaceuticals (RARE) closed down -$0.63 after Wednesday’s +$0.28, Tuesday’s +$1.31, and Monday’s +$1.31 with a negative -$0.79 or -2.40% pre-open

 

The BOTTOM LINE: Still feeling the what … uncertainty!

The 10th trading session of November followed a positive close.

Earnings are still coming!

  • Q3 Earnings coming: Arrowhead Pharma (ARWR) FY25 results on 11/25

Expect earnings’ results that meet, beat or miss revenue estimates, EPS as to pricing expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

Welcome to my world of defining the “grey’ in our universe!

  • As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

November to understand the flow:

This week:

 

  • 11/13 – Thursday closed negative with 8 positive, 32 negative and 0 flat
  • 11/12 – Wednesday closed negative with 18 positive, 22 negative and 0 flat
  • 11/11 – Tuesday closed positive with 34 positive, 4 negative and 2 flats
  • 11/10 - Monday closed positive with 26 positive, 14 negative and 0 flats

Last week:

  • 11/7 – Friday closed negative with 16 positive, 24 negative and 0 flat
  • 11/6 – Thursday closed negative with 15 positive, 24 negative and 1 flat
  • 11/5 - Wednesday closed positive with 20 positive, 18 negative and 2 flats
  • 11/4 – Tuesday closed negative with 10 positive, 30 negative and 0 flat
  • 11/3 – Monday closed negative with 10 positive, 26 negative and 4 flats

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.